343 related articles for article (PubMed ID: 22135116)
1. Economic model of a birth cohort screening program for hepatitis C virus.
McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
[TBL] [Abstract][Full Text] [Related]
3. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
McEwan P; Ward T; Yuan Y; Kim R; L'italien G
Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
[TBL] [Abstract][Full Text] [Related]
4. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
[TBL] [Abstract][Full Text] [Related]
6. Economic assessment of an anti-HCV screening program in Italy.
Ruggeri M; Coretti S; Gasbarrini A; Cicchetti A
Value Health; 2013; 16(6):965-72. PubMed ID: 24041346
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England.
Williams J; Miners A; Harris R; Mandal S; Simmons R; Ireland G; Hickman M; Gore C; Vickerman P
Value Health; 2019 Nov; 22(11):1248-1256. PubMed ID: 31708061
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and population outcomes of general population screening for hepatitis C.
Coffin PO; Scott JD; Golden MR; Sullivan SD
Clin Infect Dis; 2012 May; 54(9):1259-71. PubMed ID: 22412061
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of expanded newborn screening in Texas.
Tiwana SK; Rascati KL; Park H
Value Health; 2012; 15(5):613-21. PubMed ID: 22867769
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
[TBL] [Abstract][Full Text] [Related]
14. An evidence of high prevalence of Hepatitis C virus in Faisalabad, Pakistan.
Ahmad N; Asgher M; Shafique M; Qureshi JA
Saudi Med J; 2007 Mar; 28(3):390-5. PubMed ID: 17334466
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
[TBL] [Abstract][Full Text] [Related]
16. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
Plunkett BA; Grobman WA
Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
[TBL] [Abstract][Full Text] [Related]
18. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
19. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland.
Bruggmann P; Negro F; Bihl F; Blach S; Lavanchy D; Müllhaupt B; Razavi H; Semela D
Swiss Med Wkly; 2015; 145():w14221. PubMed ID: 26715488
[TBL] [Abstract][Full Text] [Related]
20. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.
Deuffic-Burban S; Abiteboul D; Lot F; Branger M; Bouvet E; Yazdanpanah Y
Gut; 2009 Jan; 58(1):105-10. PubMed ID: 18824553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
